GlassScriptPhysician profile
Catherine Clarke
NPI 1821036682
$1,918.64
in general payments reported to CMS, 2019-2025
21 companies · $38.20 in 2025
The $38.20 reported for 2025 was less than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $389 · 2021: $195 · 2022: $119 · 2023: $178 · 2024: $210 · 2025: $38.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.64 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.38 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $188.36 | 2021-2025 | |
| Allergan, INC. | $156.23 | 2019-2020 | |
| Astellas Pharma US INC | $153.85 | 2019-2023 | Veozah |
| Amgen INC. | $142.17 | 2019-2025 | Evenity, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $137.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $115.58 | 2019-2021 | |
| Lilly USA, LLC | $114.36 | 2019-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $111.87 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $68.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.04 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Pfizer INC. | $56.87 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.84 | 2019-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $29.58 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.20 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $22.65 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $22.41 | 2019 | |
| Abbott Laboratories | $19.35 | 2023 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $15.68 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.31 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.